5.015
Precedente Chiudi:
$4.86
Aprire:
$4.79
Volume 24 ore:
44,841
Relative Volume:
0.18
Capitalizzazione di mercato:
$55.61M
Reddito:
$52.29M
Utile/perdita netta:
$-73.52M
Rapporto P/E:
-7.5985
EPS:
-0.66
Flusso di cassa netto:
$-100.45M
1 W Prestazione:
+10.95%
1M Prestazione:
+10.71%
6M Prestazione:
+0.30%
1 anno Prestazione:
-49.60%
Precision Biosciences Inc Stock (DTIL) Company Profile
Nome
Precision Biosciences Inc
Settore
Industria
Telefono
919-314-5512
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Confronta DTIL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
DTIL
Precision Biosciences Inc
|
5.015 | 49.34M | 52.29M | -73.52M | -100.45M | -0.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.54 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.81 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.40 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
569.92 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.36 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-10 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2024-04-30 | Iniziato | Guggenheim | Buy |
2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
2022-06-09 | Downgrade | William Blair | Outperform → Mkt Perform |
2020-07-27 | Ripresa | BTIG Research | Buy |
2020-04-03 | Downgrade | Goldman | Buy → Neutral |
2020-03-05 | Iniziato | Stifel | Buy |
2020-02-25 | Iniziato | William Blair | Outperform |
2019-08-09 | Iniziato | BTIG Research | Buy |
2019-07-16 | Iniziato | H.C. Wainwright | Buy |
2019-04-22 | Iniziato | Barclays | Overweight |
2019-04-22 | Iniziato | Goldman | Buy |
2019-04-22 | Iniziato | JP Morgan | Overweight |
2019-04-22 | Iniziato | Jefferies | Buy |
Mostra tutto
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD - Contract Pharma
What analysts say about Precision BioSciences Inc. stockFree Trading Strategy Suggestions - Autocar Professional
Precision BioSciences stock rises after FDA grants orphan drug status By Investing.com - Investing.com Canada
FDA grants orphan drug status to Precision BioSciences’ DMD treatment - Investing.com Australia
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire
What drives Precision BioSciences Inc. stock priceFastest return on investment - jammulinksnews.com
Precision BioSciences Inc. Stock Analysis and ForecastFree Capital Growth Strategies - jammulinksnews.com
Precision BioSciences Secures Orphan Drug Designation for DMD Treatment, DTIL Stock News - AInvest
Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status - TipRanks
Precision BioSciences gets FDA orphan drug designations for DMD treatment By Investing.com - Investing.com Canada
Precision BioSciences reports promising DMD gene editing results By Investing.com - Investing.com Canada
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic - Business Wire
How Precision BioSciences Inc. stock performs during market volatilityFree Market Sentiment Analysis - Newser
Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’ - MSN
Why Precision BioSciences Inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
What makes Precision BioSciences Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
(DTIL) Proactive Strategies - news.stocktradersdaily.com
Precision Biosciences CFO Sells Shares to Cover Tax Obligations - TradingView
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 3000E Value Index - MarketScreener
Insider Buying: Kevin Buehler Acquires Shares of Precision BioSciences Inc (DTIL) - GuruFocus
Precision Biosciences director Brown buys $6963 in DTIL stock - Investing.com
Precision BioSciences stock jumps after FDA grants rare pediatric designation By Investing.com - Investing.com UK
A startup banks $66M to pursue ‘inclusive precision medicine’ - BioPharma Dive
precision biosciences reports voting outcomes at annual shareholder meeting By Investing.com - Investing.com Australia
precision biosciences reports voting outcomes at annual shareholder meeting - Investing.com
Precision BioSciences Holds Annual Stockholder Meeting - TipRanks
Precision BioSciences (DTIL): Rating Reaffirmed at Buy with $60 Target | DTIL Stock News - GuruFocus
Precision BioSciences: Q1 Earnings Snapshot - CT Insider
Precision BioSciences Reports Q1 2025 Financial Results - TipRanks
Transcript : Precision BioSciences, Inc.Special Call - marketscreener.com
Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus
Precision BioSciences Reports Q1 Results and Business Update - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus
Precision Biosciences Inc Azioni (DTIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):